CPHARM - CRC Study
Community Pharmacy-Based Health-Seeking Behaviour and Colorectal Cancer Screening Uptake Among Malaysian Adults
Colorectal cancer is one of the most common cancers in Malaysia and worldwide. Although it can often be prevented or treated successfully when detected early, many people in Malaysia are diagnosed at an advanced stage. Screening tests, such as the immunochemical faecal occult blood test (iFOBT), can help detect early signs of colorectal cancer; however, participation in screening remains low.
Community pharmacies are easily accessible healthcare settings where people frequently seek health advice. Pharmacists may play an important role in improving awareness and encouraging colorectal cancer screening by providing education and support. However, more information is needed to understand how people perceive and respond to pharmacy-based colorectal cancer screening.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Yen Jun Wong
- Telefonnummer: 60355146286
- E-post: yenjun.wong@monash.edu
Studer Kontakt Backup
- Navn: Chee Tao Chang
- E-post: davidcct.crc@gmail.com
Studiesteder
-
-
Selangor
-
Klang, Selangor, Malaysia, 41050
- Big Caring Group
-
Ta kontakt med:
- Shiau Hueh Yeow
- Telefonnummer: 60374531988
- E-post: shiauhueh.yeow@bigcaring.com.my
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adults aged 50 to 75 years
- Visiting participating community pharmacies during the study period
- Able to provide informed consent
- Willing to complete the study questionnaire
- Willing to provide consent for follow-up assessment of: iFOBT provision, iFOBT testing completion, iFOBT results
Exclusion Criteria:
- Previous diagnosis of colorectal cancer
- History of colonoscopy within the recommended screening interval (within past 1 year)
- Currently experiencing symptoms suggestive of colorectal cancer
- Having a first-degree relative diagnosed with colorectal cancer
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Pharmacy customers with campaign
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
|
Ingen inngripen: Pharmacy customers without campaign
Customers will receive standard pharmacy services such as medication dispensing and general health advice, but no educational materials or one-on-one education on CRC will be provided.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening
Tidsramme: From enrollment to the 8th week follow-up.
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening, measured using the Champion Health Belief Model Scale - Colorectal Cancer - Malay (CHBMS-CRC-M) subscales of perceived susceptibility, perceived benefits, and perceived barriers, between customers from pharmacies with and without the one-day awareness campaign. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Domain scores will be calculated by summing (or averaging) the items within each domain, with higher scores indicating greater perceived susceptibility, benefits or barriers. |
From enrollment to the 8th week follow-up.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of participants who were willing to accept and perform iFOBT, report iFOBT results, and follow-up if needed.
Tidsramme: From enrollment to the 8th week of follow-up
|
From enrollment to the 8th week of follow-up
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 53176
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .